drugset
drugset / Trial / NCT05983198

Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT

NCT05983198 ↗

Phase 1 Active not recruiting 33 enrolled Novartis Pharmaceuticals
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to learn if the study drug, \[225Ac\]Ac-PSMA-R2, is safe and tolerable, and has anti-tumor activity in treated patients.

Timeline

Start
2023-11-07
Primary completion
2031-03-04
Completion
2031-03-04

Drugs

EvaluationDrugModalityDoseRoute
Subject 225Ac-PSMA-R2 Unknown 7 mbq —

Indications

prostate cancer